Acne affects about 85% of Americans at some point in their lives. But British researchers report in this week's issue of The Lancet that after just one 15-minute treatment, overall acne severity was reduced by half in 31 patients three months after treatment -- with no adverse effects. Meanwhile, another 10 patients who received a sham laser treatment got little, if any, improvement.
"The critical thing is that one treatment lasts up to three months," study researcher Tony Chu, FRCP, of London's Imperial College, tells WebMD. "Our results suggest that this laser treatment could be developed as a new therapeutic approach that would allow simultaneous treatment for both active acne and associated scarring."
In fact, Chu says that's how the N-Lite laser was shown to be effective in clearing acne -- while being used to treat permanent pockmark scars that can result when pimples are prematurely popped.
"It appears that the laser energy induces the production of chemicals that reduce inflammation in the skin and prevent spots from developing," he tells WebMD. "We are currently doing research to find out exactly how this works."
But the president of the company that markets the laser in the U.S. -- which was developed in Wales -- says because N-Lite penetrates more deeply than other light therapies, it appears to have a two-pronged benefit against acne.
"Not only does it destroy the bacteria that causes acne, but it also stimulates collagen development," says Robert Trow, PhD, of USA Photonics in Nanuet, N.Y.
Its fast-pulsed laser heats small blood vessels, allows them to open and release healing "mediators" that removes redness and builds collagen. This also prevents future skin eruptions, he says. Laser Benefits
This collagen-building effect makes its useful in removing wrinkles and scars -- its primary applications in this country since 2000, when it was first approved for use. However, N-Lite has also been used to treat psoriasis, rosacea, eczema, and warts and is currently employed in some 200 dermatology practices in the U.S., says Trow.